Cold Plasma Market Projected to Reach $6.6 Billion by 2032

Clinical interest in non-thermal plasma is expanding rapidly, driven by its versatility in wound management, dermatology, and device sterilization. Atmospheric pressure systems are particularly influential, as they allow for bedside and outpatient deployment without the need for complex vacuum infrastructure. This portability is making the technology increasingly attractive for specialty clinics and hospitals looking to streamline treatment workflows.

While capital equipment, such as specialized plasma jets, currently anchors the market with a 68.4% share, the industry is pivoting toward a recurring revenue model. Manufacturers are pairing hardware sales with consumables, maintenance contracts, and clinician training to improve adoption rates. Wound healing remains the primary application, accounting for nearly 29% of current demand due to the high volume of chronic care patients requiring repeated interventions. As the sector matures, regulatory clarity and evidence-based clinical protocols will remain the primary hurdles for companies like terraplasma medical, neoplas med, and Plasmacure B.V. as they compete for a larger footprint in North American and European markets.